HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of erythroleukemia with anthracycline antibiotics and cytosine arabinoside.

Abstract
The introduction of the anthracycline antibiotics and cytosine arabinoside have significantly improved the remission induction rate for patients with acute nonlymphocytic leukemia. Erythroleukemia (M6 by French-American-British classification) has long been considered to be resistant to chemotherapy. Since 1973 we have treated 14 patients with erythroleukemia with daunorubicin 45 mg/m2 or doxorubicin 30 mg/m2 for three days and cytosine arabinoside 100 mg/m2 by continuous infusion for 7 to 10 days. Six complete remissions (43%) were obtained with remission durations of 3+, 4+, 9, 13, 29+, and 35 months. While this remission rate is somewhat lower than that obtained with other types of acute nonlymphocytic leukemia, the combination of anthracycline antibiotics and cytosine arabinoside is clearly effective against erythroleukemia. Five patients treated before mid 1976 died soon after remission induction therapy was started. Four of these five patients were treated for 6 to 9 months with prednisone, halotestin, and/or splenectomy before remission induction chemotherapy was started and three of these patients died of systemic fungal infection, suggesting that these modalities of treatment may interfere with patient tolerance to remission induction therapy. It is suggested that erythroleukemia should be treated with intensive chemotherapy soon after the diagnosis is made.
AuthorsK Tamura, H D Preisler
JournalCancer (Cancer) Vol. 51 Issue 10 Pg. 1795-9 (May 15 1983) ISSN: 0008-543X [Print] United States
PMID6572541 (Publication Type: Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Naphthacenes
  • Cytarabine
  • Doxorubicin
  • Daunorubicin
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibiotics, Antineoplastic
  • Bone Marrow (pathology)
  • Cytarabine (therapeutic use)
  • Daunorubicin (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Leukemia, Erythroblastic, Acute (complications, drug therapy)
  • Male
  • Middle Aged
  • Naphthacenes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: